Inge Oudaert[Author] - Search Results

Year	Number of Results
2019	1
2022	5
2023	3
2024	0

1

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.

Oudaert I, Van der Vreken A, Maes A, De Bruyne E, De Veirman K, Vanderkerken K, Menu E. Oudaert I, et al. Exp Hematol Oncol. 2022 Sep 1;11(1):49. doi: 10.1186/s40164-022-00303-z. Exp Hematol Oncol. 2022. PMID: 36050788 Free PMC article. Review.

2

Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis.

Van der Vreken A, Oudaert I, Ates G, Faict S, Vlummens P, Satilmis H, Fan R, Maes A, Massie A, De Veirman K, De Bruyne E, Vanderkerken K, Menu E. Van der Vreken A, et al. Among authors: oudaert i. J Pathol. 2023 Jun;260(2):112-123. doi: 10.1002/path.6066. Epub 2023 Mar 28. J Pathol. 2023. PMID: 36807305

3

Repurposing Sulfasalazine as a Radiosensitizer in Hypoxic Human Colorectal Cancer.

Kerkhove L, Geirnaert F, Rifi AL, Law KL, Gutiérrez A, Oudaert I, Corbet C, Gevaert T, Dufait I, De Ridder M. Kerkhove L, et al. Among authors: oudaert i. Cancers (Basel). 2023 Apr 18;15(8):2363. doi: 10.3390/cancers15082363. Cancers (Basel). 2023. PMID: 37190291 Free PMC article.

4

Targeting the β₂ -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.

Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, Knight JM, De Beule N, Ates G, Massie A, Moreaux J, Maes A, De Bruyne E, Vanderkerken K, Menu E, Sloan EK, De Veirman K. Satilmis H, et al. Among authors: oudaert i. J Pathol. 2023 Jan;259(1):69-80. doi: 10.1002/path.6020. Epub 2022 Nov 22. J Pathol. 2023. PMID: 36245401 Free PMC article.

5

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.

Oudaert I, Satilmis H, Vlummens P, De Brouwer W, Maes A, Hose D, De Bruyne E, Ghesquière B, Vanderkerken K, De Veirman K, Menu E. Oudaert I, et al. J Exp Clin Cancer Res. 2022 Feb 1;41(1):45. doi: 10.1186/s13046-022-02250-3. J Exp Clin Cancer Res. 2022. PMID: 35105345 Free PMC article.

6

Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma.

Zaal EA, de Grooth HJ, Oudaert I, Langerhorst P, Levantovsky S, van Slobbe GJJ, Jansen JWA, Menu E, Wu W, Berkers CR. Zaal EA, et al. Among authors: oudaert i. Mol Omics. 2022 Jan 17;18(1):19-30. doi: 10.1039/d1mo00106j. Mol Omics. 2022. PMID: 34879122

7

System Xc^- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance.

Wang F, Oudaert I, Tu C, Maes A, Van der Vreken A, Vlummens P, De Bruyne E, De Veirman K, Wang Y, Fan R, Massie A, Vanderkerken K, Shang P, Menu E. Wang F, et al. Among authors: oudaert i. Cancer Lett. 2022 Jun 1;535:215649. doi: 10.1016/j.canlet.2022.215649. Epub 2022 Mar 18. Cancer Lett. 2022. PMID: 35315341 Free article.

8

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma.

Faict S, Oudaert I, D'Auria L, Dehairs J, Maes K, Vlummens P, De Veirman K, De Bruyne E, Fostier K, Vande Broek I, Schots R, Vanderkerken K, Swinnen JV, Menu E. Faict S, et al. Among authors: oudaert i. Cancers (Basel). 2019 Nov 20;11(12):1823. doi: 10.3390/cancers11121823. Cancers (Basel). 2019. PMID: 31756922 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year